Scholar Rock (NASDAQ:SRRK) General Counsel Sells $445,757.40 in Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) General Counsel Junlin Ho sold 9,580 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $445,757.40. Following the completion of the transaction, the general counsel owned 241,545 shares in the company, valued at $11,239,088.85. This trade represents a 3.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Junlin Ho also recently made the following trade(s):

• On Friday, January 16th, Junlin Ho sold 8,016 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total transaction of $356,551.68.

Scholar Rock Stock Performance

NASDAQ SRRK traded up $0.74 during trading on Thursday, reaching $47.70. The company’s stock had a trading volume of 960,100 shares, compared to its average volume of 1,005,770. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $49.82. The firm has a 50 day moving average price of $45.12 and a 200 day moving average price of $38.23. The firm has a market capitalization of $4.87 billion, a price-to-earnings ratio of -15.14 and a beta of 0.67. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SRRK shares. Barclays raised their price objective on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research report on Friday, November 14th. JPMorgan Chase & Co. boosted their price target on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Wolfe Research initiated coverage on shares of Scholar Rock in a research note on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $51.14.

Institutional Trading of Scholar Rock

Several institutional investors and hedge funds have recently modified their holdings of SRRK. Moody Aldrich Partners LLC increased its stake in shares of Scholar Rock by 53.5% in the third quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after buying an additional 35,481 shares during the period. Norges Bank acquired a new stake in Scholar Rock during the 2nd quarter worth approximately $41,628,000. Voya Investment Management LLC boosted its position in Scholar Rock by 18.1% during the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock worth $16,503,000 after buying an additional 67,839 shares during the period. Ensign Peak Advisors Inc grew its holdings in Scholar Rock by 78.8% during the 2nd quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock worth $21,275,000 after acquiring an additional 264,693 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new position in Scholar Rock in the 3rd quarter valued at approximately $1,402,000. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).